Abstracts tagged "psoriasis"

Abstract Number: 2886 • 2015 ACR/ARHP Annual Meeting
Secukinumab Safety and Tolerability in Patients with Active Psoriatic Arthritis and Psoriasis: Results from a Pooled Safety Analysis
Philip J. Mease¹, Iain B. McInnes², Alice B. Gottlieb³, Albert Widmer⁴, Luminita Pricop⁵ and Shephard Mpofu⁴, ¹Rheumatology Research, Swedish Medical Center, Seattle, WA, ²Immunology, Infection and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Dermatology, Tufts Medical Center, Boston, MA, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has been shown to improve the signs and symptoms of psoriasis and psoriatic arthritis (PsA).1–3 Here, we…
Abstract Number: 3118 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Disease Outcomes in Psoriatic Arthritis Patients By Extent of Body Surface Area Affected By Psoriasis: Results from Corrona Registry
Philip J. Mease^1,2,3,4, Chitra Karki⁵, Carol J. Etzel^5,6, Arthur Kavanaugh⁷, Christopher T. Ritchlin⁸, Wendi Malley⁵, Vivian Herrera⁹, Jacqueline B. Palmer⁹ and Jeffrey D. Greenberg^5,10, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Seattle Rheumatology Associates, Seattle, WA, ³Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁴Clinical Professor, University of Washington School of Medicine, Seattle, WA, ⁵Corrona, LLC, Southborough, MA, ⁶University of Texas M.D. Anderson Cancer Center, Houston, TX, ⁷University of California San Diego, La Jolla, CA, ⁸Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰NYU School of Medicine, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a type of inflammatory arthritis that is commonly comorbid with the skin condition, psoriasis. A major contributor to the severity…
Abstract Number: 3119 • 2015 ACR/ARHP Annual Meeting
The Risk of Venous Thromboembolism in Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis
Alexis Ogdie-Beatty¹, Daniel Shin², Junko Takeshita², Zelma ChiesaFuxench² and Joel Gelfand³, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania Health System , Philadelphia, PA
Background/Purpose: Venous thromboembolism (VTE), the combined endpoint of deep venous thrombosis (DVT) and pulmonary embolism (PE), is a common and potentially deadly medical problem with…
Abstract Number: 3120 • 2015 ACR/ARHP Annual Meeting
The Prevalence, Incidence and Management of Hypertension, Diabetes and Hyperlipidemia in Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis
Kashif Jafri¹, Christie M. Bartels², Daniel Shin³ and Alexis Ogdie-Beatty⁴, ¹Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, ³University of Pennsylvania, Philadelphia, PA, ⁴Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriasis, psoriatic arthritis (PsA), and rheumatoid arthritis (RA) are associated with an increased risk for cardiovascular disease (CVD). While management of traditional CVD risk…
Abstract Number: 2359 • 2014 ACR/ARHP Annual Meeting
CGEN-15001, a Novel Immunomodulatory Fusion Protein of the B7 Family Induces Immune Tolerance and Shows Efficacy in Mouse Models of Rheumatoid Arthritis and Psoriasis
Iris Hecht¹, Kay McNamee², Aviad Keren³, Joseph R. Podojil⁴, Ilan Vaknin¹, Anat Oren¹, Galit Rotman¹, Eyal Neria¹, Stephen D. Miller⁴, Amos Gilhar³ and Richard O. Williams², ¹Compugen Ltd., Tel Aviv, Israel, ²Kennedy Institute of Rheumatology, Oxford University, Oxford, United Kingdom, ³Technion Institute of Technology, Haifa, Israel, ⁴Microbiology-Immunology, Northwestern University, Chicago, IL
Background/Purpose CGEN-15001 is an Fc-fusion protein consisting of the extracellular domain of a novel B7-like protein, discovered based on shared family characteristics. CGEN-15001 inhibits T…
Abstract Number: 1850 • 2014 ACR/ARHP Annual Meeting
The Incidence and Risk Factors for Psa in Patients with Psoriasis – a Prospective Cohort Study
Lihi Eder¹, Amir Haddad¹, Hua Shen², Cheryl Rosen³, Vinod Chandran¹, Richard J. Cook² and Dafna D. Gladman⁴, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose There are limited data regarding the incidence of PsA in patients with psoriasis. We aimed to estimate the incidence of PsA in a prospective…
Abstract Number: 1567 • 2014 ACR/ARHP Annual Meeting
The Spectrum of Autoimmune Ophthalmic Manifestations in Psoriatic Disease
Sergio Schwartzman¹, Anton Kolomeyer² and David Chu³, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Ophthalmology, University of Pittsburgh, Pittsburgh, PA, ³Ophthalmology, Rutgers, Newark, NJ
Background/Purpose: Psoriatic disease is characterized by the presence of psoriasis with or without an association of extra-dermal manifestations. Inflammatory forms of arthritis are the most…
Abstract Number: 1581 • 2014 ACR/ARHP Annual Meeting
Inflammatory Back Pain in Psoriasis and Psoriatic Arthritis Is Suggestive of Undiagnosed Spondyloarthropathies
Majed Khraishi¹, Heather Jones^2,3 and Annette Szumski⁴, ¹Clinical Professor of Medicine (Rheumatology), Memorial University of Newfoundland, St. John's, NF, Canada, ²Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ³Pfizer Inc., Collegeville, PA, ⁴Specialty Care, Pfizer Inc., Collegeville, PA
Background/Purpose: Patients with psoriasis (Ps) and/or psoriatic arthritis (PsA) may have clinical features suggestive of axial skeletal abnormalities and should be assessed for the presence…
Abstract Number: 632 • 2014 ACR/ARHP Annual Meeting
IL-23 Mediates Psoriasis-like Inflammation in the SKG Mouse Model of Spondyloarthropathy
Helen Benham¹, Linda Rehaume¹, Athan Baillet¹, Zaied Bhuyan¹, Jaclyn Bowman¹, Dimeng Pang¹, Kristine Kikly², Geoffrey Strutton³, Matthew Brown¹ and Ranjeny Thomas¹, ¹University of Queensland Diamantina Institute, Brisbane, Australia, ²Biotechnology Discovery Research, Eli Lilly and Co, Indianapolis, IN, ³Department of Pathology, Princess Alexandra Hospital, Brisbane, Australia
Background/Purpose Psoriasis (Ps) is a common immune-mediated inflammatory skin disease and is a well- recognised extra-articular manifestation of the spondyloathopathies (SpA). Genetic studies implicate IL-23…
Abstract Number: 628 • 2014 ACR/ARHP Annual Meeting
The Predictive Value of Cardiovascular and Metabolic Biomarkers for Progression of Atherosclerosis in Psoriatic Disease
Lihi Eder¹, Fatima Abji¹, Cheryl Rosen², Vinod Chandran¹ and Dafna D. Gladman¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose The pathophysiologic mechanisms underlying the accelerated atherosclerosis in patients with psoriatic disease (PsD) are unknown. We aimed to investigate candidate pathways involved in this…
Abstract Number: 537 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Human Anti–Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial
Alice B. Gottlieb¹, Philip J. Mease², Iain B. McInnes³, Bruce Kirkham⁴, Arthur Kavanaugh⁵, Proton Rahman⁶, Peter Nash⁷, Luminita Pricop⁸, Jiacheng Yuan⁹, Hanno Richards¹⁰ and Shephard Mpofu¹¹, ¹Tufts Medical Center, Boston, MA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³University of Glasgow, Glasgow, United Kingdom, ⁴Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ⁵UCSD School of Medicine, La Jolla, CA, ⁶Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁷University of Queensland, Brisbane, Australia, ⁸Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose Reducing the burden of skin manifestations of psoriatic arthritis (PsA) is an important aspect of disease management. Secukinumab, a human anti–IL-17A monoclonal antibody, has…
Abstract Number: 139 • 2014 ACR/ARHP Annual Meeting
Ultrasound Enthesitis in Primary Care Psoriasis Patients with Musculoskeletal Complaints
M. van der Ven¹, M.C. Karreman¹, A.E.a.M. Weel^1,2, I. Tchetverikov³, M. Vis⁴, T.E.C. Nijsten⁵, J.M.W. Hazes¹ and J.J. Luime¹, ¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ³Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁴Erasmus University Medical Center, Rotterdam, Netherlands, ⁵Dermatology, Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose: Psoriasis patients with enthesitis can classify as psoriatic arthritis since the introduction of the CASPAR classification criteria in 2006. However, the presence of a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].